DaltonTx secures £4m in seed funding to expand its AI-enabled drug discovery platform.
The seed round was backed by Redalpine, IQ Capital Partners, and Seedcamp.
DaltonTx builds adaptive, AI-enabled discovery platforms designed to integrate into pharmaceutical, biotechnology, and contract research workflows. The company aims to improve the economics and timelines of research and development for both small molecules and biologics.
London-based technology company DaltonTx has emerged from stealth with a £4m seed financing round to advance its artificial intelligence discovery platforms. The funding was provided by Redalpine, IQ Capital Partners, and Seedcamp, alongside support from Oxford University Innovation.
Co-founded by industry veterans from AstraZeneca, Exscientia, and the University of Oxford, DaltonTx provides a reasoning engine designed to support researchers across raw data, model training, and molecular design. The capital will be deployed to further scale its technology infrastructure for the life sciences sector.
From the founder
"AI offers an opportunity to transform drug discovery, but it is still incredibly challenging for organisations to build their own capabilities. DaltonTx exists to change that. We are solving high-impact challenges with adaptive AI-enabled systems that integrate into scientific workflows, evolve with every experiment, and give organisations lasting AI capability."
Garry Pairaudeau
Co-Founder at DaltonTx
Investor perspective
"What impressed us most about DaltonTx is the strength and depth of the founding team. Their unique combination of drug discovery, machine learning, and software engineering expertise positions them to lead the next generation of AI in pharma. We’re proud to back a team with the vision and execution capability to transform how medicines are discovered."
Tom Wilson
Partner, Seedcamp
